LLSC in partnership with CRS funds the Berg Translational Leukemia Research Program
We are pleased to announce the Berg Translational Leukemia Research Program is one of 15 research groups awarded new funding from the Leukemia and Lymphoma Society of Canada (LLCS) and the Cancer Research Society (CRS). The LLSC and CRS partnered to co-fund 15 teams across Canada from their 2022 Operating Grant competition.
With this generous funding, the Berg Group will be analyzing how adipocytes located in the vicinity of acute myeloid leukemia cells may protect them from treatment and possibly cause drug resistance.
Read more about this and the other funded projects at the Leukemia and Lymphoma Society of Canada website.
Congratulations to all of the other awardees!
Funding